Randomized Trial of Very Early Medication Abortion.

N Engl J Med

From the Department of Women's and Children's Health, Division of Obstetrics and Gynecology (K.B., K.G.-D.), and the Department of Clinical Sciences at Danderyd Hospital (H.K.K.), Karolinska Institutet, and the Department of Obstetrics and Gynecology, Karolinska University Hospital (K.G.-D.), Stockholm, Södertälje Hospital, Södertälje (K.B.), the Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg (T.J.-A., H.H.), the Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö (P.T.), the Department of Clinical Sciences, Lund University Faculty of Medicine, Lund (P.T.), the Department of Clinical Sciences, Obstetrics, and Gynecology, Umeå University, Umeå (M.B.), and Statisticon, Uppsala (J.B.) - all in Sweden; the Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, and Chalmers Centre, NHS Lothian - both in Edinburgh (J.R.-W., S.C.); the Departments of Obstetrics and Gynecology (F.G., J.K., O.H.) and General Practice and Primary Health Care (F.G.), University of Helsinki and Helsinki University Hospital, Helsinki, and the Division of Health and Social Services, Wellbeing Services County of Vantaa and Kerava, Vantaa (F.G.) - both in Finland; the Center for Research on Environment, Health, and Population Activities, Kathmandu (A.T.), and KIST Medical College Teaching Hospital, Lalitpur (H.T.) - both in Nepal; Family Planning Australia, Sydney Medical School, University of Sydney, and the School of Public Health, University of Technology Sydney - all in Sydney (C.B.); Women's Health, Auckland City Hospital, Auckland, New Zealand (K.S., G.G.); the Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway (M.L.); and the Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, Hvidovre (M.M.K.), and the Hospital of Southern Jutland, Aabenraa (E.K.) - both in Denmark.

Published: November 2024

AI Article Synopsis

  • The study investigated the effectiveness and safety of medication abortion using mifepristone and misoprostol in women up to 42 days of gestation without confirmed intrauterine pregnancy using ultrasound.
  • A total of 1504 women were randomly assigned to either an early-start abortion group or a standard delayed care group, and the primary outcome measured was the rate of complete abortion.
  • The results showed a nearly identical rate of complete abortion between the two groups (95.2% early-start vs 95.3% standard), indicating that starting medication abortion before confirming intrauterine pregnancy is as safe and effective as standard care.

Article Abstract

Background: Medication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a pregnancy can be visualized with ultrasonography.

Methods: We conducted a multicenter, noninferiority, randomized, controlled trial involving women requesting medication abortion at up to 42 days of gestation with an unconfirmed intrauterine pregnancy on ultrasound examination (visualized as an empty cavity or a sac-like structure without a yolk sac or embryonic pole). Participants were randomly assigned to either immediate start of abortion (early-start group) or standard-care treatment delayed until intrauterine pregnancy was confirmed (standard group). The primary outcome was complete abortion. The noninferiority margin was set at 3.0 percentage points for the absolute between-group difference.

Results: In total, 1504 women were included at 26 sites in nine countries and were randomly assigned to the early-start group (754 participants) or the standard group (750 participants). In an intention-to-treat analysis, a complete abortion occurred in 676 of 710 participants (95.2%) in the early-start group and in 656 of 688 (95.3%) in the standard group; the absolute between-group difference was -0.1 percentage points (95% confidence interval, -2.4 to 2.1). Ectopic pregnancies occurred in 10 of 741 participants (1.3%) in the early-start group and in 6 of 724 (0.8%) in the standard group, with one rupture before diagnosis (early-start group). Serious adverse events occurred in 12 of 737 participants (1.6%) in the early-start group and in 5 of 718 (0.7%) in the standard group (P = 0.10); the majority were uncomplicated hospitalizations for treatment of ectopic pregnancy or incomplete abortion.

Conclusions: Medication abortion before confirmed intrauterine pregnancy was noninferior to standard, delayed treatment with respect to complete abortion. (Funded by the Swedish Research Council and others; VEMA EudraCT number, 2018-003675-35; ClinicalTrials.gov number, NCT03989869.).

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2401646DOI Listing

Publication Analysis

Top Keywords

early-start group
24
standard group
20
medication abortion
16
intrauterine pregnancy
12
complete abortion
12
group
11
abortion
8
randomly assigned
8
percentage points
8
absolute between-group
8

Similar Publications

Behavioral therapies for the treatment of autism spectrum disorder: A systematic review.

Clinics (Sao Paulo)

December 2024

Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil; Coordinator of The Evidence-Based Medicine Department at Federação das Unimeds do Estado de São Paulo (FESP), São Paulo, SP, Brazil.

Introduction: Autism Spectrum Disorder (ASD) is a neurodevelopment spectrum characterized by persistent deficits in social communication and interpersonal interaction, along with restricted and repetitive patterns of behavior, interest, or activities. The appropriate screening and diagnosis must be realized to improve the children's prognosis. Moreover, appropriate treatments are necessary to promote better social integration and development.

View Article and Find Full Text PDF

Study Objectives: To examine 1) multidimensional sleep profiles in pre-schoolers (3-6 years) across geocultural regions and 2) differences in sleep characteristics and family practices between Majority World regions (Pacific Islands, Sub-Saharan Africa, Eastern Europe, Northeast Asia, Southeast Asia, South Asia, the Middle East and North Africa, Latin America) and the Minority World (the Western world).

Methods: Participants were 3507 pre-schoolers from 37 countries. Nighttime sleep characteristics and nap duration (accelerometer: n=1950) and family practices (parental questionnaire) were measured.

View Article and Find Full Text PDF

Associative learning via eyeblink conditioning differs by age from infancy to adulthood.

Commun Psychol

December 2024

Clinical Child and Adolescent Psychology, Mental Health Research and Treatment Center, Faculty of Psychology, Ruhr University Bochum, Bochum, Germany.

Associative learning is a key feature of adaptive behaviour and mental health, enabling individuals to adjust their actions in anticipation of future events. Comprehensive documentation of this essential component of human cognitive development throughout different developmental periods is needed. Here, we investigated age-related changes in associative learning in key developmental stages, including infancy, childhood, adolescence, and adulthood.

View Article and Find Full Text PDF

Developmental and Functional Outcomes Amongst Culturally and Linguistically Diverse Autistic Children.

J Autism Dev Disord

November 2024

Olga Tennison Autism Research Centre, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.

Children typically learn by attending to other people. Autism traits may impact access to social stimuli fundamental to early learning, increasing children's likelihood of a learning disability. Recent reports have highlighted that Autistic children from minority backgrounds have a higher likelihood of co-occurring intellectual disability.

View Article and Find Full Text PDF
Article Synopsis
  • * A randomized trial in China involved 269 patients who were assigned to start antiplatelet therapy early (3 days post-surgery) or late (30 days post-surgery) to evaluate safety and effectiveness on major cardiovascular events.
  • * The study, which involved patients mostly around 60 years old, aimed to measure occurrences of new major ischaemic events and intracranial bleeding within 90 days after surgery, and is officially registered under ClinicalTrials.gov number NCT04820972.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!